Your browser doesn't support javascript.
loading
A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE.
Zhang, Jian; Li, Huizhong; Gao, Dazhi; Zhang, Baofu; Zheng, Maojin; Lun, Mingyin; Wei, Mengxue; Duan, Rui; Guo, Maomao; Hua, Jiajun; Liu, Qian; Bai, Jin; Liu, Hui; Zheng, Junnian; Yao, Hong.
Affiliation
  • Zhang J; a Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University , Xuzhou , Jiangsu , China.
  • Li H; a Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University , Xuzhou , Jiangsu , China.
  • Gao D; a Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University , Xuzhou , Jiangsu , China.
  • Zhang B; d The Department of Radiology , Nanjing General Hospital, Nanjing Military Command of PLA , Nanjing , Jiangsu , China.
  • Zheng M; a Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University , Xuzhou , Jiangsu , China.
  • Lun M; b Department of Pathology , School of Biomedical Sciences, Xuzhou Medical University , Xuzhou , Jiangsu , China.
  • Wei M; a Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University , Xuzhou , Jiangsu , China.
  • Duan R; a Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University , Xuzhou , Jiangsu , China.
  • Guo M; a Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University , Xuzhou , Jiangsu , China.
  • Hua J; a Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University , Xuzhou , Jiangsu , China.
  • Liu Q; a Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University , Xuzhou , Jiangsu , China.
  • Bai J; a Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University , Xuzhou , Jiangsu , China.
  • Liu H; a Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University , Xuzhou , Jiangsu , China.
  • Zheng J; b Department of Pathology , School of Biomedical Sciences, Xuzhou Medical University , Xuzhou , Jiangsu , China.
  • Yao H; c The Affiliated Hospital of Xuzhou Medical University , Xuzhou , Jiangsu , China.
Cancer Biol Ther ; 19(6): 475-483, 2018 06 03.
Article in En | MEDLINE | ID: mdl-29400599
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Chemoembolization, Therapeutic / Carcinoma, Hepatocellular / Chemokines, CC / Cell- and Tissue-Based Therapy / Liver Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Cancer Biol Ther Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2018 Document type: Article Affiliation country: China Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Chemoembolization, Therapeutic / Carcinoma, Hepatocellular / Chemokines, CC / Cell- and Tissue-Based Therapy / Liver Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Cancer Biol Ther Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2018 Document type: Article Affiliation country: China Country of publication: United States